Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
NCT02624986 · Hoffmann-La Roche · PHASE1/PHASE2 · terminated · last registry update 2020-05-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.” | – | Registry record, Hoffmann-La Roche |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TP53 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-02-25Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, APR-246 + Azacitidine (NCT03072043)
- 2021-02-21Also stopped (terminated): Eleos, Inc., cenersen + Dexamethasone (NCT02243124)
- 2020-06-02Also stopped (terminated): MultiVir, Inc., Ad-P53 + Xeloda (NCT02842125)
- 2020-01-09Also stopped (withdrawn): Novartis Pharmaceuticals, HDM201 + cytarabine (NCT03760445)
- 2019-07-31Also stopped (terminated): Aprea Therapeutics, APR-246 + Dabrafenib (NCT03391050)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision